Conclusion
The form space constructed from the common organic solvents by initial solvent screening provided a systematic way of finding
ideal combinations of a good solvent, an antisolvent, and a bridging liquid for spherical agglomeration on a miniaturized
scale. The same working logic could be extended to other solvent techniques such as the spreading of cube-shaped particles,
monodispersed double emulsions, microemulsions, and organic nanocrystal fabrication (50–53). Powder characteristics of spherical
agglomerates such as percent yield, length-mean diameter, apparent density, population density, sphericity, friability index,
and angle of repose served as a selection guide for narrowing down the final feasible solvent combinations for future scale-up.
The initial solvent screening method made it possible to identify the right solvent combinations for spherical crystallization
early in drug development. This strategy, therefore, increases the possibility of direct tableting without performing granulation.
Acknowledgment
This work was supported by a grant from the National Science Council of Taiwan, R. O. C. (NSC 98-2113-M-008-008-006). Suggestions
from Jui-Mei Huang in DSC and Ching-Tien Lin in SEM, both at the National Central University's Precision Instrument Center
and High Valued Center are gratefully acknowledged.
Tu Lee* is an associate professor, and Yan Chan Su and Hung Ju Hou were graduate students in the department of Chemical and Materials Engineering, and Hsiang Yu Hsieh was a graduate student at the Institute of Materials Science and Engineering, all at National Central University, 300 Jhong-Da
Rd., Jhong-Li City 320, Taiwan, ROC, tel. +886 3 422 7151 ext. 34204, fax +886 3 425 2296, tulee@cc.ncu.edu.tw
.
To whom all correspondence should be addressed.
Submitted: Feb. 2, 2009; Accepted May 20, 2009.
References
1. T. Lee et al., Pharm. Technol.
34 (3), 72–75 (2010).
2. A.L. Grzesiak et al., J. Pharm. Sci.
92 (11), 2260–2271 (2003).
3. M.D. Tuladhar, J.E. Carless, and M.P. Summers, J. Pharm. Pharmacol. 35 (4), 208–214 (1983).
4. A. Bauer-Brandl, Intl. J. Pharm. 140 (2), 195–206 (1996).
5. B. Hegedüs and S. Görög, J. Pharm. Biomed. Analysis
3 (4), 303–313 (1985).
6. S. Sudo, K. Sato, and Y. Harano, J. Chem. Eng. Japan
24 (2), 237–242 (1991).
7. A.M. Tudor et al., Spectrochimica Acta
47A (9–10), 1389–139 (1991).
8. W.A. Bueno and E.G. Sobrinho, Spectrochimica Acta
51A (2), 287–292 (1995).
9. W.N. Richmond et al., J. Electroanalytical Chem.
448 (2) 237–244 (1998).
10. C.C. Chen and P.A. Crafts, Ind. Eng. Chem. Res. 45 (13), 4816–4824 (2006)..
11. A. Getsoian, R.M. Lodaya, and A.C. Blackburn, Int. J. Pharm.
348 (1–2), 3–9 (2008).
12. T. Lee and S.T. Hung, Pharm. Technol.
32 (1), 76–95 (2008).
13. T. Lee, C.S. Kuo, and Y.H. Chen, Pharm. Technol. 30 (10), 72–92 (2006).
14. G.J. Durant, J. Med. Chem.
20 (7), 901–906 (1977).
15. T. Hosokawa et al., Cryst. Eng. Comm. 6 (44), 243–249 (2004).
16. C. Rey-Mermet et al., Pharm. Res. 8 (5), 636–642 (1991).
17. R.A. Granberg and A.C. Rasmuson, J. Chem. Eng. Data
45 (3), 478–483 (2000).
18. A.Y. Huang and J.C. Berg, Colloids and Surfaces A: Physicochem. Eng. Aspects
215 (1-3), 241-252 (2003).
19. D. Rossetti, X. Pepin and S. J. R. Simons, J. Colloid and Interface Science
261 (1), 161–169 (2003).
20. E. Diaz-Herrera et al., J. Chem. Phys. 110 (16), 8084–8089 (1999).
21. H. Kahl, T. Wadewitz, and J. Winkelmann, J. Chem. Eng. Data
48 (6). 1500–1507 (2003).
22. Y. Kawashima and C.E. Capes, Powder Technol.
10 (1), 85–92 (1974).
23. Y. Kawashima and C.E. Capes, Powder Technol. 13 (2), 279–288 (1976).
24. Y. Kawashima, M. Okumura, and H. Takenaka, Science
216 (4550), 1127–1128 (1982).
25. Y. Kawashima et al., J. Pharm. Sci. 73 (10) 1407–1409 (1984).
26. Y. Kawashima, M. Okumura, and H. Takenaka, Powder Technol. 39 (1), 41–47 (1984).
27. Y. Kawashima et al., J. Pharm. Sci.
74 (11), 1152–1156 (1985).
28. A. Sano, Chem Pharm. Bull.
37 (8), 2183–2187 (1989).
29. Y. Kawashima et al., J. Pharm. Sci. 80 (5), 472–478 (1991).
30. K. Morishima et al., Powder Technol. 76 (1), 57–64 (1993).
31. Y. Kawashima et al., Powder Technol. 78 (2), 151–157 (1994).
32. K. Morishima et al., Int. J. Pharm.
105 (11), 11–18 (1994).
33. A.M. Garcia and E.S. Ghaly, J. Controlled Release
40 (3), 179–186 (1996).
34. A.H.L. Chow and M.W.M. Leung, Drug Dev. Ind. Pharm.
22 (4), 357–371 (1996).
35. U. Teipel, T. Heintz, and H.H. Krause, Propellants, Explosives, Pyrotechnics
25 (2), 81–85 (2000).
36. P. Szabó-Révész et al., Powder Technol. 114 (1), 118–124 (2001).
37. A.R. Paradkar et al., Drug Dev. Ind. Pharm. 28 (10), 1213–1220 (2002).
38. P. Szabó-Révész et al., J. Crystal Growth
237–239 (Part 3), 2240–2245 (2002).
39. Y. Kawashima et al., Powder Technol.
130 (1), 283–289 (2003).
40. A.P. Pawar et al., AAPS PharmSciTech.
5 (3), Article 44 (2004).
41. S. Bhadra et al., Pharm. Technol. 28 (2), 66–76 (2004).
42. M. Maghsoodi et al., Drug Dev. Ind. Pharm. 33 (11), 1216–1224 (2007).
43. J. Katta and A.C. Rasmuson, Int. J. Pharm. 348 (1–2), 61–19 (2008).
44. R. S. Abendan and J. A. Swift, Langmuir
18 (12), 4847–4853 (2002).
45. N. Rodríguez-Hornedo and D. Murphy, J. Pharm. Sci. 93 (2), 449–460 (2004).
46 F. Tian et al., J. Pharm. Sci. 96 (3), 584–594 (2007).
47. Y. Kobayashi et al, Int. J. Pharm. 193 (2), 137–146 (2000).
48. I. Katzhendler et al, J. Controlled Release 54 (1), 69–85 (1998).
49. Z. Wu et al., Cryst. Growth & Design
7 (12), 2454–2459 (2007).
50. X. Liu et al., Langmuir
21 (8), 3207–3212 (2005).
51. A.S. Utada et al., Science
308 (5721), 537–541 (2005).
52. S. Gupta and S.P. Moulik et al. J. Pharm. Sci.
97 (91), 22–45 (2008).
53. K. Ujiiye-Ishii et al., Cryst. Growth & Design
8 (2), 369–371 (2008).
|
